For global application, the outcomes of these developments, the therapies
themselves, need to be supported by a global framework of Mutual
Recognition Agreements (MRA) on the production of medical products.
This would mean that products made in any country, if produced to the
correct standard, can be applied and sold in any other country that has
signed the MRA. At present, however, there are not many MRAs in place
that deal with global markets, but having more would pave the way for
better cost-effective exploitation of developed innovations. The right
balance has to be struck between developing cost-effective therapeutics
and maintaining a margin above the cost of capital so that it makes sense
for all stakeholders.
Critically, this ties in with the necessity for an easier clinical translation
process. While internal projects within Endostem and Biodesign attempt
to increasingly address the quality of the decision making at earlier
stages, so that those concepts which clearly will not be applicable are
removed as early as possible to enable an enhanced focus on those that
will, there also needs to be a re-evaluation of the trial process itself,
specifically with regard to publicly developed therapeutics.
Streamlining and cost reduction at these later stages of development,
matched with social innovation and the integration of all of society in
understanding their own health management, will bring forward
Regenerative Medicine 2090 by 70 years.
This ‘must have’ list to some extent represents
the Holy Grail of all medical development, with
the exception that this particular grail can be
achieved. To be clear: what is being referred to
above is an apothecary which contains, on one
side, materials, in the middle, factors or drugs,
and, on the other side, the patients’ cells. They are
clinically-approved products in their own right,
but, more importantly, they have been approved
to be used in any number of combinations based
on the patients’ need as determined and tailored
by the doctor following diagnosis.
Projects such as Endostem and Biodesign are
well on the way to developing the three major
components that will permit this. Through
collaborative funding, alignment of strategies,
portfolio project management and integration
of quality infrastructures, a foundation has been
laid and a structure created. This structure
permits innovative, insightful and quality
academic and industrial research teams to work
within a series of small collaborative projects
which focus on project-specific and long-term
strategic objectives. This is permissible in spite
of the large geographic distance between the
different teams involved.
As knowledge and advances within these
collaborative structures is shared between the
partners, the outcome is that the significant
prior public investment in the laboratories
and personnel is leveraged to reduce financial
burden, enhanced by the cash injections which
focus the translational development, the
blueprint for the apothecary is established.
Global issue; globalised solutions
The increase in the ageing population globally is
known, as are the burdens. Treating ageing
per
se
isn’t going to change anything; the focus has
to be on keeping people functional; they must feel
empowered and strengthened and the sensation
of age related fragility replaced by a sense of well
being linked to a motivation to continue actively
contributing to the socioeconomy.
However, some things could be changed to
accelerate the speed at which the goals are
reached in order to maximise their impacts.
Fundamentally, the healthcare need and market
must be perceived as global, predisposing
better support for mechanisms that permit the
partnering of teams from across the globe to
work together addressing the import and export
of knowledge, innovation and development.
Pan European Networks: Science & Technology
06
157
Dr David Sassoon (UPMC Paris)
Scientific Co-ordinator, Endostem
browse
Professor Jöns Hilborn (University of Uppsala)
Scientific Co-ordinator, Biodesign
browse
Dr Jonathan Dando (Dando Weiss and Colucci Ltd)
NEURODEGENERATIVE RESEARCH
1...,147,148,149,150,151,152,153,154,155,156 158,159,160,161,162,163,164,165,166,167,...300